Exiqon Releases Data on Blood-Based Colorectal Cancer Test | GenomeWeb

Exiqon said this week that it has presented data showing its blood plasma-based microRNA PCR test for the early detection of colorectal cancer can achieve 82 percent sensitivity for detection of the cancer at 89 percent specificity.

Additional validation studies are expected to wrap up by year end, with data available for publication by the end of the first quarter of 2012. Exiqon added that it will begin a “large prospective validation study based on several thousands of individuals” early next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.